Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Uterine Cervical Neoplasms 1Testicular Germ Cell Tumor 1Stomach Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adrenocortical Carcinoma 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 3sargramostim 2tislelizumab 1spartalizumab 1milademetan 1devimistat 1dehydroftorafur 1bemarituzumab 1aldesleukin 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Interleukin-2 1IFL protocol 1Hydroxychloroquine 1Gemcitabine 1Fluorouracil 1Cetuximab 1Carboplatin 1Bevacizumab 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × milademetan × Gynecologic × Clear all
NCT05012397 2024-10-17

Milademetan in Advanced/Metastatic Solid Tumors

Rain Oncology Inc

Phase 2 Terminated
40 enrolled 13 charts
DermatologicEndocrineGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Testicular Germ Cell Tumor, Adenocarcinoma of Lung, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Adrenocortical Carcinoma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡